Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RapaLoad study of low-dose everolimus and/or physical training for prevention of postmenopausal bone loss
2023-508093-28-00Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of everolimus in osteoporosis and osteopenia (4 arms), sponsored by University Hospital Odense. Primary endpoint: Percentage change in P1NP at 24 weeks. Started Oct 2024; status: completed.
02
Drugs
everolimus
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on 2023-508093-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508093-28-00.